CL2007002618A1 - Composicion farmaceutica de liberacion modificada oral que comprende una pluralidad de mini-comprimidos con un diametro menor que 5 mm y comprendiendo un inhibidor del factor xa dentro de una matriz de uno o mas polimeros; procedimiento de preparacio - Google Patents

Composicion farmaceutica de liberacion modificada oral que comprende una pluralidad de mini-comprimidos con un diametro menor que 5 mm y comprendiendo un inhibidor del factor xa dentro de una matriz de uno o mas polimeros; procedimiento de preparacio

Info

Publication number
CL2007002618A1
CL2007002618A1 CL200702618A CL2007002618A CL2007002618A1 CL 2007002618 A1 CL2007002618 A1 CL 2007002618A1 CL 200702618 A CL200702618 A CL 200702618A CL 2007002618 A CL2007002618 A CL 2007002618A CL 2007002618 A1 CL2007002618 A1 CL 2007002618A1
Authority
CL
Chile
Prior art keywords
understanding
mini
polymers
matrix
pharmaceutical composition
Prior art date
Application number
CL200702618A
Other languages
English (en)
Spanish (es)
Inventor
Omar Abdelfattah Hu Abu-Baker
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2007002618A1 publication Critical patent/CL2007002618A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200702618A 2006-09-12 2007-09-10 Composicion farmaceutica de liberacion modificada oral que comprende una pluralidad de mini-comprimidos con un diametro menor que 5 mm y comprendiendo un inhibidor del factor xa dentro de una matriz de uno o mas polimeros; procedimiento de preparacio CL2007002618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82531406P 2006-09-12 2006-09-12

Publications (1)

Publication Number Publication Date
CL2007002618A1 true CL2007002618A1 (es) 2008-03-14

Family

ID=38835794

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702618A CL2007002618A1 (es) 2006-09-12 2007-09-10 Composicion farmaceutica de liberacion modificada oral que comprende una pluralidad de mini-comprimidos con un diametro menor que 5 mm y comprendiendo un inhibidor del factor xa dentro de una matriz de uno o mas polimeros; procedimiento de preparacio

Country Status (16)

Country Link
US (1) US20090285887A1 (enExample)
EP (1) EP2061439A1 (enExample)
JP (1) JP2010502762A (enExample)
KR (1) KR20090052346A (enExample)
CN (1) CN101516355A (enExample)
AR (1) AR062721A1 (enExample)
AU (1) AU2007296311A1 (enExample)
BR (1) BRPI0716234A2 (enExample)
CA (1) CA2662542A1 (enExample)
CL (1) CL2007002618A1 (enExample)
EA (1) EA200970267A1 (enExample)
IL (1) IL197295A0 (enExample)
MX (1) MX2009002669A (enExample)
PE (1) PE20080661A1 (enExample)
TW (1) TW200824723A (enExample)
WO (1) WO2008031782A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2010151745A1 (en) * 2009-06-25 2010-12-29 Elite Laboratories, Inc. Oral dosage forms
IL309564A (en) * 2010-02-25 2024-02-01 Pfizer Preparations containing apixaban
AU2015271995A1 (en) * 2010-02-25 2016-01-21 Bristol-Myers Squibb Holdings Ireland Apixaban formulations
CA2809263A1 (en) * 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
JP5937091B2 (ja) 2010-10-15 2016-06-22 ブレイン センティネル インコーポレイテッドＢｒａｉｎ Ｓｅｎｔｉｎｅｌ，Ｉｎｃ． 痙攣の検出装置
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
EP2819670B1 (en) * 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
EP2854759B1 (en) * 2012-05-24 2019-12-18 ratiopharm GmbH Dosage forms comprising apixaban and matrix former
EP2890366A1 (en) 2012-08-28 2015-07-08 DSM Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at least one of them is in the form of mini-tablets
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2017146709A1 (en) * 2016-02-25 2017-08-31 Mylan Inc. A unique high-shear granulation process for improved bioavailability of rivaroxaban
GB201721065D0 (en) * 2017-12-15 2018-01-31 Ondosis Ab Delivery device for drug pellets
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
WO2025150072A1 (en) * 2024-01-13 2025-07-17 Pulse Pharmaceuticals Pvt Ltd A stable oral pro-dispersion formulation and implementations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3240900A (en) * 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Also Published As

Publication number Publication date
US20090285887A1 (en) 2009-11-19
CA2662542A1 (en) 2008-03-20
AU2007296311A1 (en) 2008-03-20
AR062721A1 (es) 2008-11-26
PE20080661A1 (es) 2008-06-12
TW200824723A (en) 2008-06-16
JP2010502762A (ja) 2010-01-28
KR20090052346A (ko) 2009-05-25
EA200970267A1 (ru) 2009-08-28
BRPI0716234A2 (pt) 2013-10-15
CN101516355A (zh) 2009-08-26
WO2008031782A1 (en) 2008-03-20
IL197295A0 (en) 2009-12-24
EP2061439A1 (en) 2009-05-27
MX2009002669A (es) 2009-03-24

Similar Documents

Publication Publication Date Title
CL2012001404A1 (es) Composicion farmaceutica que comprende microparticulas compresibles recubiertas de farmaco, un recubrimiento de liberacion modificada, enmascarador del sabor, que comprende un polimero insoluble en agua y un recubrimiento compresible con un edulcorante no polimero sobre ella; composicion de tabletas de rapida desintegracion oral; metodo de preparacion.
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
AR062721A1 (es) Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
EP2424504A4 (en) MOUTH-CATCHING TABLET COMPOSITIONS WITH COMBINATIONS OF HIGH AND LOW-DOSED ACTIVE SUBSTANCES
EP2448406A4 (en) ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN WITH DELAYED RELEASE AND METHOD OF USE THEREOF
EP2025337A4 (en) TOPICAL PHARMACEUTICAL COMPOSITION
EP2017280A4 (en) METALOCENCIPLEX AND POLYMERIZATION CATALYST COMPOSITION THEREIN
EP2486918A4 (en) PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND DELAYED RELEASE
EP2005959A4 (en) TOPICAL PHARMACEUTICAL COMPOSITION
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
AR069875A1 (es) Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
CL2008000095A1 (es) Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen
EP2133096A4 (en) IN THE MOUTHING TABLET
CL2007002371A1 (es) Metodo para administrar un agente terapeutico que comprende administrar una composicion de nanoparticulas que comprende una matriz polimerica junto con un cation divalente que contiene un agente terapeutico; y dicha composicion.
EP2059183A4 (en) BIOMEDICAL NANOTHERAPEUTICS ACTIVATED IN DENTAL AND MEDICAL TREATMENTS, AND METHODS OF PROCESSING ENERGETICALLY ACTIVATED
ATE542815T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
CL2007003565A1 (es) Compuestos derivados de piperidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion vih.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
CL2007003108A1 (es) Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington,
CR10349A (es) Tabletas de paracetamol de liberacion rapida
EP2003970A4 (en) FORMULATIONS OF LOW-DOSEED NON-STEROID INFLAMMATORY INHIBITORS AND BETA-CYCLODEXTRIN
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
EP2474522A4 (en) AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
UY33076A (es) Microcápsulas de fexofenadina y composiciones que las contienen